Implanted Tile-Based Radiation Therapy Demonstrates Superior Outcomes in Brain Metastases Treatment
A novel approach using tile-based radiation therapy (TBRT) has shown promising results in the management of brain metastases, according to findings from the phase III Radiation One and Done Study (ROADS) presented at the 2026 ASCO Annual Meeting. This technique, applied at the time of tumor resection, was reported to offer better control of the surgical bed and increased overall survival compared to standard postoperative stereotactic radiation therapy (SRT).
Jeffrey S. Weinberg, MD, from The University of Texas MD Anderson Cancer Center, highlighted the gap in care that occurs when radiation treatment is delayed post-surgery, potentially impacting local control and delaying systemic therapy. He emphasized the need for improved treatment options that streamline logistics and enhance outcomes.
The trial evaluated the implantation of 2 × 2-cm collagen-based tiles with cesium-131 brachytherapy seeds immediately post-resection. These tiles delivered a targeted radiation dose of 100 to 120 Gy to the cavity wall. Over 90% of the radiation was administered within five weeks. The study reported that median time to surgical bed recurrence was not reached in the TBRT group versus 17.4 months in the SRT group (hazard ratio [HR] = 0.06; P = .007), with a significant improvement in surgical bed recurrence-free survival.
David Schiff, MD, of the University of Virginia School of Medicine, noted that this approach could replace conventional cavity radiosurgery if further validated. The trial involved 230 patients across 32 sites, with 204 meeting criteria for the modified intention-to-treat analysis. Results also indicated more than a twofold increase in median overall survival for patients treated with TBRT—42.5 months compared to 17.6 months for the SRT group (HR = 0.59; P = .032).
Secondary outcomes such as functional status, quality of life, and adverse events were comparable between both treatment arms. However, TBRT significantly reduced the risk of surgical bed recurrence or radiation necrosis over time.
Despite its open-label design, which poses certain limitations, the researchers highlighted that TBRT was associated with a reduced likelihood of recurrence in treated areas and contributed to prolonged survival without increased toxicity. Further analysis is ongoing to assess the influence of concurrent oncologic therapies and evaluate TBRT in other brain tumor contexts, including glioblastoma.
These results suggest that TBRT, with its potential for improved local control and logistics, may become a new standard for treating brain metastases, pending further investigation and validation of findings.